Pharmaceutical

DMTs are major clinical research focus for Parkinson’s disease, analysis shows

GlobalData analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's disease treatments.

Nov 13, 2024 - 06:00
DMTs are major clinical research focus for Parkinson’s disease, analysis shows
GlobalData analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's disease treatments.
Read the original article

Tags:

Previous Article

Are dry powder inhalers the key to sustainable respiratory care?

Next Article

Uppsala and KTH Royal develop antibody for potential cancer treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CTO Europe 2023: Cancer clinical trials shift as sector goes digital

CTO Europe 2023: Cancer clinical trials shift as sector...

Nov 28, 2023

STAT+: What to know about Sarepta’s upcoming data on its Duchenne gene therapy

STAT+: What to know about Sarepta’s upcoming data on it...

Oct 30, 2023

STAT+: In ‘march-in’ rights, some see a tool to lower drug prices. Others see a threat to intellectual property

STAT+: In ‘march-in’ rights, some see a tool to lower d...

Jan 22, 2024